Clinical trial
Efficacy of Sirolimus-Based, Steroid Avoidance Immunosuppression African…
NCT00189202 · University of Michigan, Other · Completed
Key facts
| NCT number | NCT00189202 |
|---|---|
| Title | Efficacy of Sirolimus-Based, Steroid Avoidance Immunosuppression African Americans |
| Official title | Efficacy of Sirolimus-Based, Steroid Avoidance Maintenance Immunosuppression in Black de Novo Kidney Transplant Recipients |
| Lead sponsor | University of Michigan, Other |
| Collaborators | Wyeth is now a wholly owned subsidiary of Pfizer Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | End Stage Renal Disease, Kidney Transplantation |
| Intervention type | Drug |
| Interventions | Sirolimus |
| Enrollment | 49 |
| Start date | Aug 1, 2004 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Sep 16, 2005 |
| Last update posted | Mar 27, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: